- Do Steroid Shots Help Ease Back Pain? Experts Weigh In
- Americans Who’ve Become Caregivers Rose by a Third in 10 Years
- Epstein-Barr Virus Might Help Trigger Cancer After Kidney Transplant
- Seniors, Could Working Later in Life Be Healthy?
- Zoo Workers Battle Grief When Animals in Their Care Die
- Number Infected Now 24 in Texas County Measles Outbreak
- Depression Can Speed Onset of Chronic Illnesses, Study Finds
- RFK Jr. Confirmed as Health Secretary in Near Party-Line Vote
- Belly Fat, Diabetes and Drinking Doubles Liver Disease Risk
- Experts Warn Marijuana Ads Are Reaching Kids Through Social Media
Perjeta Approved for Early Stage Breast Cancer

MONDAY, Sept. 30The anti-cancer drug Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat early-stage breast cancer before surgery, the agency said Monday.
In 2012, the drug was approved to treat advanced or spreading (metastatic) HER-2 positive breast cancer, which is triggered by increased amounts of a protein that fuels the growth of cancer cells, the FDA said in a news release.
The drug’s new use is meant for people with HER-2 positive early-stage breast cancer who are at increased risk of the cancer returning, spreading or of dying from the disease, the agency said. The drug is to be used with in combination with chemotherapy before surgery.
Perjeta’s safety and effectiveness were evaluated for the new use in a clinical study involving 417 people, the FDA said. A “confirmatory” study involving more than 4,800 people is ongoing, with results expected in 2016.
Perjeta is marketed by San Francisco-based Genentech, a member of the Roche Group.
More information
To learn more about this approval, visit the FDA.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.